Quick Answer
Allogene Therapeutics, Inc. reported Net Income of -$190.89 million for fiscal year 2025.
Allogene Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$190.89M | +25.9% |
| 2024 | -$257.59M | +21.3% |
| 2023 | -$327.26M | +3.9% |
| 2022 | -$340.41M | -87.0% |
| 2021 | -$182.05M | +27.2% |
| 2020 | -$250.22M | -35.6% |
| 2019 | -$184.59M | +12.7% |
| 2018 | -$211.50M | -10575150.0% |
| 2017 | -$2.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$41.40M | +37.5% | +18.7% |
| June 30, 2025 | -$50.94M | +23.2% | +14.7% |
| March 31, 2025 | -$59.73M | +8.1% | +9.9% |
| September 30, 2024 | -$66.29M | -6.4% | +0.1% |
| June 30, 2024 | -$66.36M | +16.2% | -2.1% |
| March 31, 2024 | -$65.00M | +35.0% | -4.4% |
| September 30, 2023 | -$62.29M | +25.1% | +21.4% |
| June 30, 2023 | -$79.23M | -5.9% | +20.7% |
- Allogene Therapeutics, Inc. showed an increase of +25.9% in Net Income compared to the prior fiscal year.
- Over the 2017–2025 period, Allogene Therapeutics, Inc.’s net income has declined by 9544200.0% (from -$2.0 thousand to -$190.89 million).
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: